biostudies-literatureCastro MDMTDRMedical Research Councile0011029https://www.ebi.ac.uk/biostudies/studies/S-EPMC9894540biostudies-literatureUnknown17(1)<h4>Background</h4>Treatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.<h4>Methods</h4>We conducted a collaborative retrospective study to describe the effectiveness and safety of antileishmanial treatments in children ≤ 10 and adults ≥ 60 years of age, treated between 2014 and 2018 in ten CL referral centers in Latin America.<h4>Results</h4>2,037 clinical records were assessed for eligibility. Of them, the main reason for non-inclusion was lack of data on treatment follow-up and therapeutic response (182/242, 75% of children and 179/468, 38% of adults). Data on 1,325 eligible CL patients (736 children and 589 older adults) were analyzed. In both age groups, disease prePLoS neglected tropical diseasesCutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.PMC9894540MR/R010161/1202114150Quintero JSuprien CArenas CMArana BRamos APVelez IDMachado PRLCastro MDMCota GRojas EAlexander NArantes RBDSHueb Mda Silva REPimentel MIFAlvarez FLyra MRRojas IVRode JSoto JOrobio YSaravia NGOviedo Sarmiento OLlanos-Cuentas AfalseCutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.<h4>Background</h4>Treatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.<h4>Methods</h4>We conducted a collaborative retrospective study to describe the effectiveness and safety of antileishmanial treatments in children ≤ 10 and adults ≥ 60 years of age, treated between 2014 and 2018 in ten CL referral centers in Latin America.<h4>Results</h4>2,037 clinical records were assessed for eligibility. Of them, the main reason for non-inclusion was lack of data on treatment follow-up and therapeutic response (182/242, 75% of children and 179/468, 38% of adults). Data on 1,325 eligible CL patients (736 children and 589 older adults) were analyzed. In both age groups, disease pre2023-01-01T00:00:00Z2023 Jan2026-07-16T20:10:59.449Z2025-04-06T15:42:11.558ZS-EPMC98945403668946510.1371/journal.pntd.0011029